mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)

Area of Science:

• Oncology
• Molecular Biology
• Gastroenterology

Background:

• Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are increasingly diagnosed, presenting heterogeneous and often metastatic disease.
• Current treatments for metastatic GEP-NENs include surgery, radiological interventions, and therapies like somatostatin analogs and PRRT.
• The PI3K-AKT-mTOR pathway is crucial for cell growth and metabolism, and its dysregulation is implicated in various cancers.

Purpose of the Study:

• To review the role of the PI3K-AKT-mTOR pathway in the development of GEP-NENs.
• To explore the potential of targeting the PI3K-AKT-mTOR pathway in advanced GEP-NENs.
• To discuss challenges related to targeted therapy resistance and clinical trial design for GEP-NENs.

Main Methods:

• Literature review of molecular studies on the PI3K-AKT-mTOR pathway in GEP-NENs.
• Analysis of evidence linking pathway over-activation to malignant progression and treatment resistance.
• Synthesis of current understanding of targeted therapy mechanisms and resistance in GEP-NENs.

Main Results:

• The PI3K-AKT-mTOR pathway is frequently deregulated in GEP-NENs, suggesting its involvement in tumorigenesis.
• Over-activation of this pathway can contribute to malignant progression and resistance to existing therapies.
• Mechanisms of resistance to targeted therapy, including feedback activation and component deregulation, are significant challenges.

Conclusions:

• The PI3K-AKT-mTOR pathway represents a promising therapeutic target for advanced GEP-NENs.
• Further research is needed to define the specific role and optimal application of targeted drugs, addressing resistance mechanisms.
• Understanding pathway dynamics is critical for developing effective treatment strategies for neuroendocrine tumors.